Price range: $51.00 through $168.00
Looking to buy Tirzepatide for your research? Our lab-verified >98% pure Tirzepatide multi-dose vials are trusted by researchers worldwide for metabolic, glycemic control, and obesity research studies. In stock – ready to ship within 24 hours.
✅ Lab-Tested >98% Purity (COA Included)
✅ Dual GIP and GLP-1 Receptor Agonist
✅ Multi-Dose Vials: 5mg, 10mg, 20mg, 30mg, 60mg
✅ Fast, Discreet Shipping Worldwide
✅ Trusted by Leading Research Institutions
Tirzepatide is a once-weekly injectable peptide that belongs to a class of drugs known as dual GIP and GLP-1 receptor agonists. It works by mimicking two naturally occurring gut hormones—glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)—to regulate key metabolic functions.
When you buy Tirzepatide from Mega Protide, you’re getting a research-grade peptide that has been third-party tested for purity and potency. This Tirzepatide research peptide is widely used in metabolic, glycemic control, and obesity research.
| Parameter | Details |
|---|---|
| Type | Dual GIP/GLP-1 Receptor Agonist |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| Molecular Weight | ~4813.5 Da |
| CAS Number | 2023788-19-2 |
| Form | Lyophilized powder |
| Available Strengths | 5mg, 10mg, 20mg, 30mg, 60mg per vial |
| Purity | >98% by HPLC |
| Storage | Refrigerate at 2-8°C (36-46°F); protect from light |
| Route | Subcutaneous injection |
| Half-Life | ~5 days |
| Dosing Frequency | Once weekly |
Tirzepatide exerts its effects through dual receptor activation:
| Receptor | Mechanism | Effect |
|---|---|---|
| GIP Receptor | Activates GIP receptors on pancreatic beta-cells | Enhances glucose-dependent insulin secretion |
| GLP-1 Receptor | Activates GLP-1 receptors on pancreatic beta-cells | Stimulates insulin secretion, suppresses glucagon |
| Central Appetite | Signals fullness to the brain | Reduces appetite and caloric intake |
| Gastric Emptying | Slows gastric emptying | Promotes prolonged satiety |
| Metabolic Regulation | Modulates glucose and lipid metabolism | Improves glycemic control |
Key Advantage: Tirzepatide is the first and only dual GIP/GLP-1 receptor agonist, offering complementary mechanisms that provide superior glycemic control and weight reduction compared to selective GLP-1 agonists.
The strengths listed (5mg, 10mg, 20mg, 30mg, 60mg) represent the total amount of Tirzepatide contained in each multi-dose vial, not a single injection dose.
| Total Vial Strength | Purpose |
|---|---|
| 5mg Vial | Total 5mg medication – ideal for short-term or low-dose research |
| 10mg Vial | Total 10mg medication – suitable for early titration studies |
| 20mg Vial | Total 20mg medication – provides multiple doses for extended research |
| 30mg Vial | Total 30mg medication – provides multiple doses for extended research |
| 60mg Vial | Total 60mg medication – provides multiple doses for extended research |
Tirzepatide therapy follows a gradual step-up approach. The standard single-injection dose strengths range from 2.5mg up to 15mg once weekly:
| Phase | Duration | Dose |
|---|---|---|
| Starting Phase | First 4 weeks | 2.5 mg once weekly |
| Titration Phase | Gradual increases every 4 weeks | 5mg → 7.5mg → 10mg → 12.5mg → 15mg |
| Maintenance Phase | Stable weekly dose | 5mg to 15mg once weekly |
Important: The larger multi-dose vials (20mg, 30mg, 60mg) offer flexibility by containing enough medication for multiple weekly injections as the dose increases over time.
| Application | Research Focus | Status |
|---|---|---|
| Type 2 Diabetes | Glycemic control, insulin secretion, HbA1c reduction | FDA-approved (Mounjaro®) |
| Obesity Research | Appetite regulation, weight reduction, energy expenditure | FDA-approved (Zepbound®) |
| Dual GIP/GLP-1 Research | Receptor signaling, metabolic pathways | Active research |
| Cardiovascular Research | CV risk reduction, metabolic health | Active research |
| MASLD/MASH Research | Hepatic fat reduction, inflammation modulation | Active research |
| Metabolic Research | Insulin sensitivity, lipid metabolism | Extensive research |
| Parameter | Finding |
|---|---|
| Glycemic Control | Superior HbA1c reduction vs selective GLP-1 agonists |
| Weight Reduction | Up to 20% weight loss in clinical trials |
| Dual Mechanism | First and only dual GIP/GLP-1 receptor agonist |
| Half-Life | ~5 days (once-weekly dosing) |
| Cardiovascular Benefit | Reduces cardiovascular risk factors |
| Satiety Effect | Promotes sustained fullness and reduced caloric intake |
| Titration Schedule | Gradual step-up from 2.5mg to 15mg weekly |
| Study | Year | Finding |
|---|---|---|
| SURPASS Trials | 2021-2022 | Tirzepatide showed superior glycemic control vs semaglutide |
| SURMOUNT Trials | 2022-2023 | Tirzepatide achieved up to 20% weight reduction in obesity |
| SURPASS-2 Trial | 2021 | Tirzepatide 10mg and 15mg superior to semaglutide 1mg |
| SURMOUNT-1 Trial | 2022 | Significant weight reduction in adults with obesity |
| SURMOUNT-2 Trial | 2023 | Efficacy in adults with type 2 diabetes and obesity |
| Cardiovascular Outcomes | 2024+ | Ongoing CVOT studies |
📖 Over 5 years of peer-reviewed research support Tirzepatide research utility.
Add 1-2ml bacteriostatic water to the Tirzepatide vial
Gently swirl – do not shake
Refrigerate at 2-8°C
Use within 30 days of reconstitution
| Parameter | Recommendation |
|---|---|
| Starting Dose | 2.5 mg once weekly (first 4 weeks) |
| Titration Doses | 5mg, 7.5mg, 10mg, 12.5mg, 15mg (increase every 4 weeks) |
| Maintenance Dose | 5mg to 15mg once weekly |
| Route | Subcutaneous injection |
| Half-Life | ~5 days |
| Storage | Refrigerate at 2-8°C after reconstitution |
| Protect from Light | Store in original carton until ready for use |
| Parameter | Details |
|---|---|
| Temperature | Refrigerate at 2-8°C (36-46°F) |
| Light Protection | Protect from light; store in original carton |
| Freezing | Do not freeze |
| Reconstituted | Use within 30 days |
| Aspect | Details |
|---|---|
| Boxed Warning | Risk of thyroid C-cell tumors (rodent studies); relevance to humans unknown |
| Contraindications | Personal/family history of MTC, MEN 2, hypersensitivity |
| Common Side Effects | Nausea, vomiting, diarrhea, constipation (GI effects diminish over time) |
| Serious Side Effects | Pancreatitis, gallbladder disease, hypoglycemia, acute kidney injury, hypersensitivity |
| Limitations | Not for type 1 diabetes; not studied in patients with pancreatitis history |
| Long-Term Data | Long-term safety and efficacy established |
| Lifestyle Modifications | Intended for use alongside diet and exercise |
| Advantage | Why It Matters |
|---|---|
| Lab-Verified >98% Purity | Third-party HPLC testing ensures quality and consistency |
| Multiple Vial Strengths | 5mg, 10mg, 20mg, 30mg, 60mg options for various research protocols |
| Multi-Dose Flexibility | Vials provide multiple doses for extended research |
| COA Included | Full transparency with every Tirzepatide order |
| Fast Shipping | Orders processed within 24 hours |
| Discreet Packaging | Privacy guaranteed |
Tirzepatide is supplied for research and laboratory use only. Not for human consumption. Not for therapeutic or diagnostic use. Use only by qualified researchers in controlled laboratory settings. Not FDA-approved for human use outside approved clinical protocols.
| Weight | 5mg, 10mg, 20mg, 30mg, 60mg |
|---|
Always available!
Comes with each order!
Get access to expert resources.
Reviews
There are no reviews yet.